NCT05704309
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
Enrolling by Invitation
Not specifiedAll AgesObservationalMarinella TemprosaInvestigator-initiated
~1,976 participants
Updated 2025-08-26 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cognitive Diagnoses
Measured over Sept 2022 to October 2026
Conditions
Where it's being run
27 sites across 18 statesNew Mexico3
New York3
California2
Illinois2
Maryland2
Massachusetts2
Pennsylvania2
Arizona1
Study leadership
- Jose Luchsinger · PRINCIPAL_INVESTIGATOR · Columbia University
- David Nathan · STUDY_CHAIR · Massachusetts General Hospital
- Marinell Temprosa · PRINCIPAL_INVESTIGATOR · George Washington University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
All surviving participants originally randomized in the Diabetes Prevention Program
For Brain Imaging subcohort, only participants aged 55 years and older and those without contraindication to MRI will be included. Contraindications to MRI include the inability to lie flat, claustrophobia, and the presence of indwelling metallic objects, medical or non-medical, that are not 3T MRI compatible.
What this trial measures
- Cognitive DiagnosesSept 2022 to October 2026
Classification of normal, mild cognitive impairment or dementia based on NACC UDS